Publications by authors named "Angelique N Voorberg"
Article Synopsis
- Vesicular hand eczema (VHE) has shown limited response to the standard treatment alitretinoin, highlighting the need for new treatment options.
- The study constructed a gene network from differentially expressed genes and quantitative trait locus genes linked to hand eczema to explore biological mechanisms.
- By analyzing drug-gene interactions, the researchers identified 123 potential drug repurposing candidates, with a focus on vitamin D analogues, retinoids, and immunomodulating drugs as the most promising treatments for VHE.
Article Synopsis
- Scientists studied skin conditions called vesicular hand eczema (VHE) and atopic dermatitis (AD) to find out how they are similar and different.
- They looked at genes in skin samples from both conditions and found many genes that were active in both types of eczema, but also some that were unique to VHE.
- The results showed VHE has some different features and signaling processes compared to AD, suggesting they might be related but also have their own unique traits.
Background: Effective treatment options for patients with chronic hand eczema (CHE) are scarce. Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis and has shown promising results for the treatment of hand eczema in other studies.
Objectives: To evaluate the efficacy and safety of dupilumab in adult patients with severe CHE (subtypes recurrent vesicular hand eczema or chronic fissured hand eczema) who have an inadequate response/intolerance to alitretinoin, or when alitretinoin is medically inadvisable.
Efficacy and safety of oral alitretinoin versus oral azathioprine in patients with severe chronic hand eczema: Results from a prematurely discontinued randomized controlled trial.
Contact Dermatitis
October 2022
Background: The hands are a common predilection site of atopic dermatitis (AD). Dupilumab is licensed for the treatment of AD but not for chronic hand eczema (CHE), while CHE is challenging to treat.
Objectives: To evaluate the long-term effect of dupilumab on hand eczema (HE) in patients with AD from the BioDay Registry.
Article Synopsis
- Hand eczema is a widespread inflammatory skin condition, which necessitates up-to-date treatment information for healthcare providers.
- The European Society of Contact Dermatitis aimed to refresh their guidelines on the diagnosis, prevention, and treatment of hand eczema through a committee that reviewed the latest evidence and created new consensus strategies.
- The updated guidelines are expected to enhance the way hand eczema is managed by healthcare professionals.
Data on chronic hand eczema and severity of hand eczema in the general population is scarce. In this cross-sectional study, a questionnaire was sent to 135,950 Lifelines Cohort Study participants, in order to investigate the prevalence and severity of hand eczema in the Dutch general population. In total, 57,798 subjects were included.
View Article and Find Full Text PDFHand eczema is a common inflammatory skin condition of the hands whose pathogenesis is largely unknown. More insight and knowledge of the disease on a more fundamental level might lead to a better understanding of the biological processes involved, which could provide possible new treatment strategies. We aimed to profile the transcriptome of lesional palmar epidermal skin of patients suffering from vesicular hand eczema using RNA-sequencing.
View Article and Find Full Text PDFBackground: Eczema control is a new construct to be measured in atopic dermatitis (AD).
Objectives: Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 and 52 weeks.
Methods: Cross-sectional questionnaire study.
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
J Am Acad Dermatol
April 2021
Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included.
Systemic treatment options for chronic hand eczema are limited. Dupilumab is used in atopic dermatitis (AD) but is not licensed for (isolated) hand eczema. In this observational prospective study we aimed to determine the response of hand eczema to dupilumab in patients with AD.
View Article and Find Full Text PDFBackground: Dupilumab, the first registered biological for the treatment of atopic dermatitis, frequently causes adverse ocular events. These often take the form of mild conjunctivitis or blepharoconjunctivitis, however, more serious adverse ocular events have also been reported, including limbal stem cell insufficiency.
Case Description: A 56-year-old man was treated with dupilumab for severe atopic dermatitis.